-
Product Insights
Limbal Stem Cell Deficiency (LSCD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Limbal Stem Cell Deficiency (LSCD) - Drugs In Development, 2023’, provides an overview of the Limbal Stem Cell Deficiency (LSCD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Limbal Stem Cell Deficiency (LSCD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TPX-107 in Limbal Stem Cell Deficiency (LSCD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TPX-107 in Limbal Stem Cell Deficiency (LSCD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TPX-107 in Limbal Stem Cell Deficiency (LSCD)Drug Details:TPX-107 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CUG-252 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CUG-252 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CUG-252 in Systemic Lupus Erythematosus Drug Details: CUG-252 is under development...
-
Company Profile
Chiesi Farmaceutici SpA – Company Profile
Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces and commercializes novel medicines with a focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome, lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD) and inflammatory bowel diseases, among others. The company operates production sites in Parma, Italy; Blois, France; and Santana De...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TPX-107
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TPX-107 Drug Details TPX-107 is under development for the treatment of Limbal stem cell...